Institutions / Perceptive Advisors LLC / Activity
Activity — Perceptive Advisors LLC
112 moves.
| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q1 2026 as of | Exit | Exact Sciences Corp. Common stock | $-121.92M | -1.2M -100.00% | 0 | high |
| Q1 2026 as of | Add | Ascendis Pharma A/S Common stock | $102.93M | +450K +41.61% | 1,531,421 6.92% of portfolio | high |
| Q1 2026 as of | Exit | Arcellx, Inc. Common stock | $-95.59M | -1.5M -100.00% | 0 | high |
| Q1 2026 as of | Exit | Boston Scientific Corp Common stock | $-93.35M | -979K -100.00% | 0 | high |
| Q1 2026 as of | Add | 152309100 Common stock | $93.00M | +2.3M +80.25% | 5,258,903 4.13% of portfolio | high |
| Q1 2026 as of | Exit | Amicus Therapeutics Inc Common stock | $-90.72M | -6.4M -100.00% | 0 | high |
| Q1 2026 as of | Exit | 04635X102 Common stock | $-84.89M | -6.5M -100.00% | 0 | high |
| Q1 2026 as of | Add | Relay Therapeutics, Inc. Common stock | $78.09M | +7.8M +412.34% | 9,751,141 1.92% of portfolio | high |
| Q1 2026 as of | Trim | Apogee Therapeutics, Inc. Common stock | $-66.52M | -790K -33.91% | 1,540,384 2.56% of portfolio | high |
| Q1 2026 as of | Exit | Danaher Corp /De Common stock | $-45.78M | -200K -100.00% | 0 | medium |
| Q1 2026 as of | Trim | BLTE Belite Bio, Inc ADR | $-41.81M | -262K -63.31% | 151,979 0.48% of portfolio | medium |
| Q1 2026 as of | Add | Biocryst Pharmaceuticals Inc Common stock | $40.66M | +4.3M +135.07% | 7,434,033 1.40% of portfolio | medium |
| Q1 2026 as of | New | Ionis Pharmaceuticals Inc Common stock | $37.85M | +504K | 504,000 0.75% of portfolio | medium |
| Q1 2026 as of | New | Day One Biopharmaceuticals, Inc. Common stock | $37.64M | +1.8M | 1,755,799 0.74% of portfolio | medium |
| Q1 2026 as of | Trim | Viridian Therapeutics, Inc. Common stock | $-36.61M | -1.9M -61.52% | 1,170,829 0.45% of portfolio | medium |
| Q1 2026 as of | Exit | 171757206 Common stock | $-36.48M | -165K -100.00% | 0 | medium |
| Q1 2026 as of | Add | Spyre Therapeutics, Inc. Common stock | $36.01M | +714K +23.26% | 3,783,225 3.77% of portfolio | medium |
| Q1 2026 as of | Exit | IRON Disc Medicine, Inc. Common Stock | $-35.79M | -451K -100.00% | 0 | medium |
| Q1 2026 as of | Trim | Neurocrine Biosciences Inc Common stock | $-35.04M | -266K -80.35% | 65,050 0.17% of portfolio | medium |
| Q1 2026 as of | Exit | Penumbra Inc Common stock | $-34.36M | -111K -100.00% | 0 | medium |
| Q1 2026 as of | New | 36322Q206 Common stock | $31.68M | +1.2M | 1,223,000 0.63% of portfolio | medium |
| Q1 2026 as of | Exit | Caris Life Sciences, Inc. Common stock | $-30.65M | -1.1M -100.00% | 0 | medium |
| Q1 2026 as of | Exit | 75382E208 Common stock | $-27.97M | -826K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | PVLA Palvella Therapeutics, Inc. Common Stock | $-27.87M | -266K -100.00% | 0 | medium |
| Q1 2026 as of | New | Revolution Medicines, Inc. Common stock | $25.15M | +259K | 258,600 0.50% of portfolio | medium |
| Q1 2026 as of | Exit | KOD Kodiak Sciences Inc. Common Stock | $-23.74M | -849K -100.00% | 0 | medium |
| Q1 2026 as of | Add | Corvus Pharmaceuticals, Inc. Common stock | $23.41M | +1.6M +231.07% | 2,292,441 0.66% of portfolio | medium |
| Q1 2026 as of | Exit | Biogen Inc. Common stock | $-21.82M | -124K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | Aldeyra Therapeutics, Inc. Common stock | $-21.68M | -4.2M -100.00% | 0 | medium |
| Q1 2026 as of | Add | Dyne Therapeutics, Inc. Common stock | $21.57M | +1.2M +34.20% | 4,668,839 1.67% of portfolio | medium |
| Q1 2026 as of | Add | SAB Biotherapeutics, Inc. Common stock | $21.56M | +5.6M +700.75% | 6,431,743 0.49% of portfolio | medium |
| Q1 2026 as of | Trim | Sionna Therapeutics, Inc. Common stock | $-20.87M | -521K -44.16% | 658,439 0.52% of portfolio | medium |
| Q1 2026 as of | Exit | Mirum Pharmaceuticals, Inc. Common stock | $-20.50M | -260K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | GRAIL, Inc. Common stock | $-20.31M | -237K -100.00% | 0 | medium |
| Q1 2026 as of | Trim | OMDA Omada Health, Inc. Common Stock | $-20.24M | -1.6M -67.19% | 786,330 0.20% of portfolio | medium |
| Q1 2026 as of | New | DBVT Dbv Technologies S.A. ADR | $20.15M | +964K | 964,391 0.40% of portfolio | medium |
| Q1 2026 as of | New | Sutro Biopharma, Inc. Common stock | $17.82M | +715K | 715,307 0.35% of portfolio | medium |
| Q1 2026 as of | Exit | CVS HEALTH Corp Common stock | $-17.46M | -220K -100.00% | 0 | medium |
| Q1 2026 as of | Add | Tenax Therapeutics, Inc. Common stock | $16.13M | +1.0M +229.68% | 1,447,782 0.46% of portfolio | medium |
| Q1 2026 as of | Exit | Glaukos Corp Common stock | $-15.81M | -140K -100.00% | 0 | medium |
| Q1 2026 as of | Trim | Rhythm Pharmaceuticals, Inc. Common stock | $-15.01M | -173K -6.78% | 2,373,795 4.08% of portfolio | medium |
| Q1 2026 as of | Exit | Dexcom Inc Common stock | $-14.98M | -226K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | SVRA Savara Inc Common Stock | $-14.47M | -2.4M -100.00% | 0 | medium |
| Q1 2026 as of | Trim | 00370M103 Common stock | $-14.42M | -129K -28.25% | 328,884 0.72% of portfolio | medium |
| Q1 2026 as of | Add | Guardant Health, Inc. Common stock | $12.93M | +140K +87.50% | 300,000 0.55% of portfolio | medium |
| Q1 2026 as of | Add | Praxis Precision Medicines, Inc. Common stock | $12.89M | +40K +2.00% | 2,035,986 12.96% of portfolio | medium |
| Q1 2026 as of | Trim | Protagonist Therapeutics Inc Common stock | $-12.60M | -120K -8.85% | 1,230,879 2.56% of portfolio | medium |
| Q1 2026 as of | Exit | SEPN Septerna, Inc. Common Stock | $-12.08M | -433K -100.00% | 0 | medium |
| Q1 2026 as of | Trim | Opus Genetics, Inc. Common stock | $-11.33M | -2.5M -57.55% | 1,835,842 0.16% of portfolio | medium |
| Q1 2026 as of | New | EVMN Evommune, Inc. Common Stock | $10.31M | +448K | 448,350 0.20% of portfolio | medium |